Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06516029 · ClinicalTrials.gov registry record
Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib
A clinical trial, sponsored by Novartis.
- Completed
- Registry status
- 111
- Enrollment target
NCT06516029 is a clinical trial that has completed, run by Novartis. The registered enrollment target is 111 participants.
The verdict
NCT06516029 has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- 111 participants
- Enrollment target
Study Summary
A retrospective, non-interventional cohort study design using data obtained from the Flatiron Health oncology electronic health record (EHR)-derived de-identified database, was used to address the study objectives. The overall asciminib cohort included adult patients with Philadelphia positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CML-CP), with or without the T3151 mutation, who initiated asciminib in any line of therapy. The third-line or later (3L+) asciminib cohort included adult patients with Ph+ CML-CP who did not have T315I mutation and initiated asciminib after prior use of at least 2 different tyrosine kinase inhibitors (TKIs) or omacetaxine. The 3L asciminib cohort included the subgroup of the 3L+ asciminib cohort who initiated asciminib after prior use of 2 different TKIs or omacetaxine. The fourth-line or later (4L+) asciminib cohort included the subgroup of the 3L+ asciminib cohort who initiated asciminib after prior use of at least 3 different TKIs or omacetaxine.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2023-04-21 |
| Est. Completion | 2023-10-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06516029
The ClinicalTrials.gov registry entry for NCT06516029 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06516029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06516029 about?
NCT06516029 is a clinical study titled "Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib". A retrospective, non-interventional cohort study design using data obtained from the Flatiron Health oncology electronic health record (EHR)-derived de-identified database, was used to address the study objectives. The overall asciminib cohort included adult patients with Philadelphia positive (Ph+...
What is the current status of trial NCT06516029?
This trial is currently completed. The enrollment target is 111 participants. The study started on 2023-04-21. Estimated completion is 2023-10-02.
Who is sponsoring clinical trial NCT06516029?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.